Eva Rye Rasmussen
Research Subjects
Eva Rye Rasmussen has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Anette Bygum
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
19 shared publications - Christian von Buchwald
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Rigshospitalet, University of Copenhagen Copenhagen Denmark
5 shared publications Helge Arndal
Private Hospital Valdemar, 4100, Ringsted, Denmark
4 shared publicationsKristianna Mey
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Rigshospitalet and Gentofte Hospital, University of Copenhagen Copenhagen Denmark
4 shared publicationsEva Lykke
Department of Oto-Rhino-Laryngology, Head and Neck Surgery, University Hospital of Copenhagen, Blegdamsvej 9B, 2100, Copenhagen East, Denmark
3 shared publications- Mia Wadelius
Department of Medical Sciences, Clinical Pharmacogenomics Uppsala University Uppsala Sweden
3 shared publications
Latest Publications
- 14 April 2021
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 22 (6) , 319-321
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
- 14 April 2021
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 22 (6) , 319-321
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
- Open Access
- 1 July 2020
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 13, 225-236
Clinical Features and Disease Course of Primary Angioedema Patients in a Tertiary Care Hospital
Purpose: To give a better understanding of primary AE, the clinical characteristics and the possible therapeutic approaches. Background: Angioedema (AE) is a non-pitting, non-itching swelling of skin or mucosa. The symptom can become life-threatening if located in the airways. Primary (monosymptomatic) AE is a manifestation of several different diseases and the diagnosis is not always straight-forward. The aetiological and pathophysiological factors of primary AE are not completely clarified. There is a need for further investigation. Patients and Methods: This was a retrospective cohort study of patients referred to an outpatient dermatology clinic in a tertiary care hospital for clinical assessment due to primary AE in the period from 1996 to 2014. Results: A total of 315 patients were identified with primary AE. The most frequent subtype was idiopathic AE (42.5%) and the second most common was angiotensin-converting enzymeinhibitor (ACEi)-induced AE (31.1%). Three patients were diagnosed with hereditary AE and one patient was diagnosed with acquired C1-inhibitor deficiency. At least 107 (34.0%) patients had established histaminergic AE. More than 1/3 of the patients were treated in an emergency room or hospitalized due to AE. A 98.1% of patients had experienced AE in the head and neck area. Seven patients were in the need of acute airway intervention. Six of these had ACEi-induced AE. Female sex and smoking were found to be risk factors for developing AE. Conclusion: The most frequent diagnoses were histaminergic-, non-histaminergic idiopathic AE and ACEi-induced AE, whereas complement C1-inhibitor deficiency was rare. Histaminergic AE made up a substantial group of patients with primary AE. Even though there are different pathophysiological causes of AE, many cases have overlapping clinical manifestations, which make diagnosis and treatment difficult.
- 1 July 2020
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 13, 225-236
Open AccessClinical Features and Disease Course of Primary Angioedema Patients in a Tertiary Care Hospital
Purpose: To give a better understanding of primary AE, the clinical characteristics and the possible therapeutic approaches. Background: Angioedema (AE) is a non-pitting, non-itching swelling of skin or mucosa. The symptom can become life-threatening if located in the airways. Primary (monosymptomatic) AE is a manifestation of several different diseases and the diagnosis is not always straight-forward. The aetiological and pathophysiological factors of primary AE are not completely clarified. There is a need for further investigation. Patients and Methods: This was a retrospective cohort study of patients referred to an outpatient dermatology clinic in a tertiary care hospital for clinical assessment due to primary AE in the period from 1996 to 2014. Results: A total of 315 patients were identified with primary AE. The most frequent subtype was idiopathic AE (42.5%) and the second most common was angiotensin-converting enzymeinhibitor (ACEi)-induced AE (31.1%). Three patients were diagnosed with hereditary AE and one patient was diagnosed with acquired C1-inhibitor deficiency. At least 107 (34.0%) patients had established histaminergic AE. More than 1/3 of the patients were treated in an emergency room or hospitalized due to AE. A 98.1% of patients had experienced AE in the head and neck area. Seven patients were in the need of acute airway intervention. Six of these had ACEi-induced AE. Female sex and smoking were found to be risk factors for developing AE. Conclusion: The most frequent diagnoses were histaminergic-, non-histaminergic idiopathic AE and ACEi-induced AE, whereas complement C1-inhibitor deficiency was rare. Histaminergic AE made up a substantial group of patients with primary AE. Even though there are different pathophysiological causes of AE, many cases have overlapping clinical manifestations, which make diagnosis and treatment difficult.
- Open Access
- 1 December 2019
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 11, 105-113
ACE-Inhibitor Related Angioedema Is Not Sufficiently Reported to the Danish Adverse Drug Reactions Database
Purpose: The primary objective of this study was to calculate the report rate of angiotensin-converting enzyme inhibitor-related angioedema (ACEi-AE). Secondary objectives were to determine factors suspected to affect the likelihood of ACEi-AE being reported and to investigate potential differences in angioedema risks between different ACEis. Patients and methods: Patient data from two cohorts comprising 176 patients with ACEi-AE were compared with report data from the Danish Adverse Drug Reactions Database, administered by the Danish Medicines Agency (DKMA). The study period was 1994–2015. Data were linked using unique personal identification numbers and birth dates. Cohort data and report data were compared with ACEi sales numbers from MedStat, an official database containing annual pharmaceutical drug sale data in Denmark. Results: ACEi-AE was reported in two out of 176 cases resulting in a report rate of 1.1%, meaning that 98.9% of the cases were not reported. Since 1994, a total of 417 ACEi-AE reports were made to the DKMA. Fifty-eight percent of these were made by general practitioners or physicians with unknown workplaces and 35% by hospital staff. Enalapril and ramipril were the most sold ACEi’s in the study period (40.3% and 42.6%, respectively). Enalapril was associated with 54.7% of ACEi-AE reports while ramipril was associated with 14.2%. ACEi substance received was known for 141 cohort patients, of which 53.9% were prescribed enalapril and 17.0% received ramipril. Conclusion: ACEi-AE was found to be severely underreported in Denmark, greatly limiting the available incidence data for this potentially life-threatening adverse reaction.
- 1 December 2019
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 11, 105-113
Open AccessACE-Inhibitor Related Angioedema Is Not Sufficiently Reported to the Danish Adverse Drug Reactions Database
Purpose: The primary objective of this study was to calculate the report rate of angiotensin-converting enzyme inhibitor-related angioedema (ACEi-AE). Secondary objectives were to determine factors suspected to affect the likelihood of ACEi-AE being reported and to investigate potential differences in angioedema risks between different ACEis. Patients and methods: Patient data from two cohorts comprising 176 patients with ACEi-AE were compared with report data from the Danish Adverse Drug Reactions Database, administered by the Danish Medicines Agency (DKMA). The study period was 1994–2015. Data were linked using unique personal identification numbers and birth dates. Cohort data and report data were compared with ACEi sales numbers from MedStat, an official database containing annual pharmaceutical drug sale data in Denmark. Results: ACEi-AE was reported in two out of 176 cases resulting in a report rate of 1.1%, meaning that 98.9% of the cases were not reported. Since 1994, a total of 417 ACEi-AE reports were made to the DKMA. Fifty-eight percent of these were made by general practitioners or physicians with unknown workplaces and 35% by hospital staff. Enalapril and ramipril were the most sold ACEi’s in the study period (40.3% and 42.6%, respectively). Enalapril was associated with 54.7% of ACEi-AE reports while ramipril was associated with 14.2%. ACEi substance received was known for 141 cohort patients, of which 53.9% were prescribed enalapril and 17.0% received ramipril. Conclusion: ACEi-AE was found to be severely underreported in Denmark, greatly limiting the available incidence data for this potentially life-threatening adverse reaction.
- Open Access
- 11 November 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (11) , e0224858
Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches
Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II which causes vasoconstriction. ACE inhibitors reduce blood pressure by inhibiting ACE. A well-known adverse drug reaction to ACE inhibitors is ACE inhibitor-induced angioedema (ACEi-AE). Angioedema is a swelling of skin and mucosa, which can be fatal if the airway is compromised. We have performed a systematic review of the evidence suggesting that genetic polymorphisms are associated with ACEi-AE and evaluated the methodological approaches of the included studies. The Cochrane Database of Systematic Reviews, Google Scholar, and PubMed were searched. Studies investigating the association between genetic markers and ACEi-AE were included. The Q-genie tool was used to evaluate the quality of the study methodologies. Seven studies were included. With the exception of one whole genome study, all of the included studies were candidate gene association studies. Study quality assessment scores ranged from 36 to 55. One study was found to be of good quality, suggesting that the detected associations may be unreliable. The inferior quality of some studies was due to poor organization, lack of analyses and missing information. Polymorphisms within XPEPNP2, BDKRB2–9/+ 9 and neprilysin genes, were reported to be associated with increased risk of ACEi-AE. However, due to low quality, these associations need to be confirmed in larger studies.
- 11 November 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (11) , e0224858
Open AccessGenetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches
Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II which causes vasoconstriction. ACE inhibitors reduce blood pressure by inhibiting ACE. A well-known adverse drug reaction to ACE inhibitors is ACE inhibitor-induced angioedema (ACEi-AE). Angioedema is a swelling of skin and mucosa, which can be fatal if the airway is compromised. We have performed a systematic review of the evidence suggesting that genetic polymorphisms are associated with ACEi-AE and evaluated the methodological approaches of the included studies. The Cochrane Database of Systematic Reviews, Google Scholar, and PubMed were searched. Studies investigating the association between genetic markers and ACEi-AE were included. The Q-genie tool was used to evaluate the quality of the study methodologies. Seven studies were included. With the exception of one whole genome study, all of the included studies were candidate gene association studies. Study quality assessment scores ranged from 36 to 55. One study was found to be of good quality, suggesting that the detected associations may be unreliable. The inferior quality of some studies was due to poor organization, lack of analyses and missing information. Polymorphisms within XPEPNP2, BDKRB2–9/+ 9 and neprilysin genes, were reported to be associated with increased risk of ACEi-AE. However, due to low quality, these associations need to be confirmed in larger studies.
- Open Access
- 4 September 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (9) , e231122
Acquired complement C1 esterase inhibitor deficiency in a patient with a rare SERPING1 variant with unknown significance
Angioedema (AE) is caused by a wide range of diseases and pharmaceuticals; it can become life-threatening when located to the airways. Patients with deficiency or malfunction of complement C1 esterase inhibitor (hereditary or acquired) experience recurrent AE due to an accumulation of the vasoactive mediator bradykinin (BK). Complement C1 inhibitor normally decreases BK production, so a reduced function hereof causes increased levels. The diagnosis of hereditary or acquired AE can be difficult due to similarities to allergic reactions (swelling, abdominal pain, rash). We describe a 35-year-old man presenting with upper-airway AE progressing rapidly and promptly required cricothyroidotomy. Complement and autoantibody screening together with sequencing of SERPING1 were performed and gave the diagnosis of acquired complement C1 esterase inhibitor deficiency. The patient is unusual to have this disease before the age of 40 years. No associated comorbidities were found. It is important to know that antiallergic medication is not effective in BK-mediated AE.
- 4 September 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (9) , e231122
Open AccessAcquired complement C1 esterase inhibitor deficiency in a patient with a rare SERPING1 variant with unknown significance
Angioedema (AE) is caused by a wide range of diseases and pharmaceuticals; it can become life-threatening when located to the airways. Patients with deficiency or malfunction of complement C1 esterase inhibitor (hereditary or acquired) experience recurrent AE due to an accumulation of the vasoactive mediator bradykinin (BK). Complement C1 inhibitor normally decreases BK production, so a reduced function hereof causes increased levels. The diagnosis of hereditary or acquired AE can be difficult due to similarities to allergic reactions (swelling, abdominal pain, rash). We describe a 35-year-old man presenting with upper-airway AE progressing rapidly and promptly required cricothyroidotomy. Complement and autoantibody screening together with sequencing of SERPING1 were performed and gave the diagnosis of acquired complement C1 esterase inhibitor deficiency. The patient is unusual to have this disease before the age of 40 years. No associated comorbidities were found. It is important to know that antiallergic medication is not effective in BK-mediated AE.
- 28 November 2018
- Published by Wiley in Journal of Internal Medicine
- Vol. 285 (5) , 553-561
Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin‐converting enzyme inhibitors – a nationwide registry‐based cohort study
Background: It has long been suggested that angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (AT2s) have some degree of ‘cross‐reactivity' in causing angioedema. Therefore, caution has been advised when switching patients with ACEi‐related angioedema to an AT2.Objectives: To clarify whether AT2s can be used safely in patients with a history of angioedema during ACEi treatment and to estimate the incidence rate of angioedema in patients subsequently treated with other antihypertensive drugs (beta‐adrenergic blockers, calcium channel blockers, thiazides and analogues) or no antihypertensives.Methods: This is a nationwide retrospective registry‐based cohort study of the Danish population during the period 1994 to 2016, and it uses Danish health registries. Propensity score adjusted and conventional proportional hazards regression models have been employed.Results: A total of 1 106 024 ACEi users were identified. In total, 5 507 (0.5%) of these patients had experienced angioedema during ACEi treatment and were included in the study. The highest risk of angioedema recurrence was associated with continued ACEi use at an adjusted hazard ratio of 1.45 (95% CI, 1.19 to 1.78). An inverse association was found between AT2s and angioedema (adjusted hazard ratio, 0.39; 95% CI, 0.30 to 0.51) compared with other antihypertensives (adjusted hazard ratios, 0.77 to 0.97).Conclusions: Compared with other antihypertensive drugs, AT2s do not increase the incidence of angioedema in patients with previous ACEi‐related angioedema.
- 28 November 2018
- Published by Wiley in Journal of Internal Medicine
- Vol. 285 (5) , 553-561
Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin‐converting enzyme inhibitors – a nationwide registry‐based cohort study
Background: It has long been suggested that angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (AT2s) have some degree of ‘cross‐reactivity' in causing angioedema. Therefore, caution has been advised when switching patients with ACEi‐related angioedema to an AT2.Objectives: To clarify whether AT2s can be used safely in patients with a history of angioedema during ACEi treatment and to estimate the incidence rate of angioedema in patients subsequently treated with other antihypertensive drugs (beta‐adrenergic blockers, calcium channel blockers, thiazides and analogues) or no antihypertensives.Methods: This is a nationwide retrospective registry‐based cohort study of the Danish population during the period 1994 to 2016, and it uses Danish health registries. Propensity score adjusted and conventional proportional hazards regression models have been employed.Results: A total of 1 106 024 ACEi users were identified. In total, 5 507 (0.5%) of these patients had experienced angioedema during ACEi treatment and were included in the study. The highest risk of angioedema recurrence was associated with continued ACEi use at an adjusted hazard ratio of 1.45 (95% CI, 1.19 to 1.78). An inverse association was found between AT2s and angioedema (adjusted hazard ratio, 0.39; 95% CI, 0.30 to 0.51) compared with other antihypertensives (adjusted hazard ratios, 0.77 to 0.97).Conclusions: Compared with other antihypertensive drugs, AT2s do not increase the incidence of angioedema in patients with previous ACEi‐related angioedema.
- Open Access
- 1 March 2018
- Published by Wiley in International Journal of Otolaryngology
- Vol. 2018, 1
Corrigendum to “Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema”
[This corrects the article DOI: 10.1155/2017/1476402.].
- 1 March 2018
- Published by Wiley in International Journal of Otolaryngology
- Vol. 2018, 1
Open AccessCorrigendum to “Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema”
[This corrects the article DOI: 10.1155/2017/1476402.].
- 11 January 2018
- Published by Wiley in Clinical Otolaryngology
- Vol. 43 (3) , 854-860
A prospective cohort study of 122 adult patients presenting to an otolaryngologist's office with globus pharyngeus
Objectives: To investigate the epidemiology of globus pharyngeus in adult patients presenting to the otolaryngologist's office. Also, the predictors of persisting symptoms, prevalence of anxiety and the effect of clinical assessment were analysed.Design: This was a prospective cohort study. Follow‐up was carried out using a postal questionnaire.Setting: One otolaryngologists’ office comprising three medical doctors.Participants: A total of 122 consecutive globus patients presenting to one otolaryngology office in a 1‐year period.Main outcome measures: Globus incidence, gender and age distribution, predictors of persisting symptoms and the patient's health‐related concerns.Results: 3.8% of first‐time visits were regarding globus. The mean age was 48 years [range 20‐88 years], and a female predominance was found (ratio 1.49). Eighty‐four per cent experienced anxiety, mainly due to fear of cancer. The most common pathological findings were reflux (15.6%) and post‐infectious inflammation (10.6%). 21.4% of questionnaire responders reported full remission of their symptoms. Three predictors regarding symptom persistence were identified: male gender (OR 1.52), smoking (OR 3.4) and difficulties in breathing (OR 8.7). Patients with concomitant foreign body sensation were less likely to have persisting symptoms (OR 0.42). No cases of malignant disease were encountered. 94.7% was reassured by the office visit.Conclusion: The incidence of globus is 3.8% in the otolaryngologist's office. Female gender and concomitant foreign body sensation were predictive for presenting to the clinic even if symptom remission had occurred. Male gender, smoking and self‐perceived breathing difficulties were predictive for persisting symptoms. Globus is an anxiety‐causing symptom, but reassurance is provided by clinical examination by the otolaryngologist.
- 11 January 2018
- Published by Wiley in Clinical Otolaryngology
- Vol. 43 (3) , 854-860
A prospective cohort study of 122 adult patients presenting to an otolaryngologist's office with globus pharyngeus
Objectives: To investigate the epidemiology of globus pharyngeus in adult patients presenting to the otolaryngologist's office. Also, the predictors of persisting symptoms, prevalence of anxiety and the effect of clinical assessment were analysed.Design: This was a prospective cohort study. Follow‐up was carried out using a postal questionnaire.Setting: One otolaryngologists’ office comprising three medical doctors.Participants: A total of 122 consecutive globus patients presenting to one otolaryngology office in a 1‐year period.Main outcome measures: Globus incidence, gender and age distribution, predictors of persisting symptoms and the patient's health‐related concerns.Results: 3.8% of first‐time visits were regarding globus. The mean age was 48 years [range 20‐88 years], and a female predominance was found (ratio 1.49). Eighty‐four per cent experienced anxiety, mainly due to fear of cancer. The most common pathological findings were reflux (15.6%) and post‐infectious inflammation (10.6%). 21.4% of questionnaire responders reported full remission of their symptoms. Three predictors regarding symptom persistence were identified: male gender (OR 1.52), smoking (OR 3.4) and difficulties in breathing (OR 8.7). Patients with concomitant foreign body sensation were less likely to have persisting symptoms (OR 0.42). No cases of malignant disease were encountered. 94.7% was reassured by the office visit.Conclusion: The incidence of globus is 3.8% in the otolaryngologist's office. Female gender and concomitant foreign body sensation were predictive for presenting to the clinic even if symptom remission had occurred. Male gender, smoking and self‐perceived breathing difficulties were predictive for persisting symptoms. Globus is an anxiety‐causing symptom, but reassurance is provided by clinical examination by the otolaryngologist.
- 1 December 2017
- Vol. 64 (12)
Long-term follow-up and outcome in patients with recurrent respiratory laryngeal papillomatosis.
Recurrent respiratory papillomatosis is characterized by wart-like lesions of the upper airway and is most frequently caused by human papillomavirus (HPV). The disease has significant impact on quality of life due to potential airway obstruction, dysphonia and the need for serial surgeries. The main objective of this study was to describe patient characteristics and long-term follow-up data in a Danish cohort with the disease. The study was a longitudinal retrospective cohort-study using data from electronic medical records and a pathology database. A total of 61 adult and four juvenile patients were identified. The male-to-female ratio was 2.4. In the adult population, the mean age at onset was 45 years. The median number of surgeries was four (interquartile range: 2.8). The mean follow-up time was 8.7 years (range: 7 days-30 years). Three cases of malignant transformation were observed. In the juvenile population, the mean age of onset was 8.5 years (range: 3-12 years). The mean follow-up time was 11.5 years (range: 2-23 years), and the number of surgeries per year at risk was one/year. CO2-laser and microdebrider were the surgical techniques usually employed. 43% of histopathologic analyses could detect HPV infection (subtype 6 or 11). More males than females suffer from respiratory papillomatosis; age of onset was either in childhood or in mid-life. Use of CO2-laser or microdebrider was the preferred surgical approach in this cohort. none. not relevant.
- 1 December 2017
- Vol. 64 (12)
Long-term follow-up and outcome in patients with recurrent respiratory laryngeal papillomatosis.
Recurrent respiratory papillomatosis is characterized by wart-like lesions of the upper airway and is most frequently caused by human papillomavirus (HPV). The disease has significant impact on quality of life due to potential airway obstruction, dysphonia and the need for serial surgeries. The main objective of this study was to describe patient characteristics and long-term follow-up data in a Danish cohort with the disease. The study was a longitudinal retrospective cohort-study using data from electronic medical records and a pathology database. A total of 61 adult and four juvenile patients were identified. The male-to-female ratio was 2.4. In the adult population, the mean age at onset was 45 years. The median number of surgeries was four (interquartile range: 2.8). The mean follow-up time was 8.7 years (range: 7 days-30 years). Three cases of malignant transformation were observed. In the juvenile population, the mean age of onset was 8.5 years (range: 3-12 years). The mean follow-up time was 11.5 years (range: 2-23 years), and the number of surgeries per year at risk was one/year. CO2-laser and microdebrider were the surgical techniques usually employed. 43% of histopathologic analyses could detect HPV infection (subtype 6 or 11). More males than females suffer from respiratory papillomatosis; age of onset was either in childhood or in mid-life. Use of CO2-laser or microdebrider was the preferred surgical approach in this cohort. none. not relevant.
- 13 September 2017
- Published by Wiley in Clinical Otolaryngology
- Vol. 43 (1) , 274-284
A nationwide registry‐based cohort study of incidence of tonsillectomy in Denmark, 1991‐2012
Objective: To update tonsillectomy incidence rates in Denmark and identify whether the incidence rates vary between geographical areas in the country during the period 1991‐2012.Design: This was a retrospective nationwide cohort study using data from the comprehensive Danish patient registries. Data included surgical code, gender and date of birth, date and place of surgery.Setting: Hospitals and private oto‐, rhino‐, laryngology (ORL) offices.Participants: Danes who underwent tonsillectomy in the period 1991‐2012.Main outcome measure: Tonsillectomy.Results: In the 22‐year period, 177 211 tonsillectomies were conducted, and the overall incidence of tonsillectomy decreased significantly over time. The overall annual incidence of tonsillectomies decreased from 155.7 per 100 000 inhabitants in 1991 to 129.4 per 100 000 inhabitants in 2012. In 1991, 5.5% of tonsillectomies were performed in office settings, while in 2012, it had increased to 26.6% (P < .01). The highest incidence of tonsillectomy was found in children between 3 and 4 years of age (predominance of males, P < .01) and in 15‐ to 19‐year‐olds (predominance of females, P < .01). Each year, 0.44% of children underwent tonsillectomy, and by the age of 20, 7.7% of the Danish people has had a tonsillectomy. There were significant regional differences in the number of tonsillectomies.Conclusion: The incidence rate of tonsillectomies in Denmark decreased significantly in the study period, but with great regional variance.
- 13 September 2017
- Published by Wiley in Clinical Otolaryngology
- Vol. 43 (1) , 274-284
A nationwide registry‐based cohort study of incidence of tonsillectomy in Denmark, 1991‐2012
Objective: To update tonsillectomy incidence rates in Denmark and identify whether the incidence rates vary between geographical areas in the country during the period 1991‐2012.Design: This was a retrospective nationwide cohort study using data from the comprehensive Danish patient registries. Data included surgical code, gender and date of birth, date and place of surgery.Setting: Hospitals and private oto‐, rhino‐, laryngology (ORL) offices.Participants: Danes who underwent tonsillectomy in the period 1991‐2012.Main outcome measure: Tonsillectomy.Results: In the 22‐year period, 177 211 tonsillectomies were conducted, and the overall incidence of tonsillectomy decreased significantly over time. The overall annual incidence of tonsillectomies decreased from 155.7 per 100 000 inhabitants in 1991 to 129.4 per 100 000 inhabitants in 2012. In 1991, 5.5% of tonsillectomies were performed in office settings, while in 2012, it had increased to 26.6% (P < .01). The highest incidence of tonsillectomy was found in children between 3 and 4 years of age (predominance of males, P < .01) and in 15‐ to 19‐year‐olds (predominance of females, P < .01). Each year, 0.44% of children underwent tonsillectomy, and by the age of 20, 7.7% of the Danish people has had a tonsillectomy. There were significant regional differences in the number of tonsillectomies.Conclusion: The incidence rate of tonsillectomies in Denmark decreased significantly in the study period, but with great regional variance.